Protego Biopharma closed a $130 million Series B round to advance PROT‑001, an orally available small molecule candidate for AL (light‑chain) amyloidosis, into a potential pivotal study. The financing round was oversubscribed and led by major life‑science investors including Novartis Venture Fund and Forbion. The company says PROT‑001 stabilizes pathogenic immunoglobulin light chains and will move toward larger trials next year. Backing from experienced rare‑disease investors underscores confidence in the program’s differentiated mechanism relative to prior antibody approaches. The capital will be used for clinical development and to scale operations; success could offer a new therapeutic class in a disease where recent antibody efforts have struggled in late‑stage testing.